Study: NCT02924688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (100/31.25/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily \[QD\] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (100/62.5/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (200/31.25/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (200/62.5/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI (100/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI (100/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI (100/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI (100/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/VI (100/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/VI (100/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/VI (200/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (FSC)
Description: Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (FSC)
Description: Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (FSC)
Description: Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (FSC)
Description: Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/salmeterol (FSC)
Description: Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/salmeterol (FSC)
Description: Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.